Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 5/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.44 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HPGD | P15428 | 1/20 | 0.38 |
| ▸ | ITGB1 | P05556 | 2/20 | 0.36 |
| ▸ | ITGA4 | P13612 | 2/20 | 0.36 |
| ▸ | WDR5 | P61964 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | F2R | P25116 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26462366 | 0.84 | ITGB3 (0.35) | ITGB3ITGA2BSMN1; SMN2ITGB1ITGA4 | |
| SCHEMBL20158349 | 0.80 | STS (0.56) | ALDH1A1MEN1KMT2AMAPTL3MBTL1 | |
| SCHEMBL20157749 | 0.79 | HDAC1 (0.41) | ITGB3ITGA2BSMN1; SMN2 | |
| SCHEMBL20141286 | 0.77 | ITGB1 (0.35) | ITGB3ITGA2BSMN1; SMN2ITGB1ITGA4 | |
| SCHEMBL21317519 | 0.75 | STS (0.41) | ITGB3ITGA2BALDH1A1ITGB1ITGA4 | |
| SCHEMBL20156329 | 0.74 | L3MBTL1 (0.44) | SMN1; SMN2ALDH1A1GAAWDR5MEN1 | |
| SCHEMBL20156328 | 0.74 | L3MBTL1 (0.44) | SMN1; SMN2ALDH1A1GAAWDR5MEN1 | |
| SCHEMBL20156327 | 0.74 | L3MBTL1 (0.44) | SMN1; SMN2ALDH1A1GAAWDR5MEN1 | |
| SCHEMBL24036755 | 0.74 | L3MBTL1 (0.42) | ITGB3SMN1; SMN2ALDH1A1GAAHPGD | |
| SCHEMBL30487482 | 0.72 | HDAC1 (0.34) | ITGB3ITGA2BITGB1ITGA4WDR5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2021-08-12 | — | — | US | disclosed |
| WO-2018089355-A1 | CYCLOBUTANE- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-05-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210246136-A1 | CYCLOBUTANES- AND AZETIDINE-CONTAINING MONO AND SPIROCYCLIC COMPOUNDS AS ALPHA V INTEGRIN INHIBITORS | ITGB1, ITGAV, ITGA1 | ITGB3 7/4885ITGA2B 5/4885SMN1; SMN2 2721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.